Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: A prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B

Haemophilia

Volumn 20, Issue 1, 2014, Pages 15-24

  Windyga, J ^a   Lissitchkov, T ^b   Stasyshyn, O ^c   Mamonov, V ^d   Rusen, L ^e   Lamas, J L ^f   Oh, M S ^g   Chapman, M ^h   Fritsch, S ^h   Pavlova, B G ^h   Wong, W Y ^g   Abbuehl, B E ^h  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^b Specialized Hematological Hospital Joan Pavel   (Bulgaria)

^c Hematology Department of the Academy of Medical Sciences of Ukraine   (Ukraine)

^d NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^e National Hematology Institute Prof Dr CT NICOLAU   (Romania)

^f HOSPITAL DR SÓTERO DEL RÍO   (Chile)

^g BAXTER HEALTHCARE CORPORATION   (United States)

^h BAXTER BIOSCIENCE   (Austria)

Author keywords

BAX326; Haemophilia B; Previously treated patients; Recombinant factor IX

Indexed keywords

BAX 326; RECOMBINANT BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DYSGEUSIA; FEMALE; HEMOPHILIA B; HEMOSTASIS; HUMAN; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

BAX326; HAEMOPHILIA B; PREVIOUSLY TREATED PATIENTS; RECOMBINANT FACTOR IX;

ADOLESCENT; ADULT; AGED; BLOOD COAGULATION; CHILD; FACTOR IX; FEMALE; HEMOPHILIA B; HUMANS; MALE; MIDDLE AGED; PREMEDICATION; QUALITY OF LIFE; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890859035     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12228     Document Type: Article

References (40)

1. Castaldo G, Nardiello P, Bellitti F et al. Haemophilia B: from molecular diagnosis to gene therapy. Clin Chem Lab Med 2003; 41: 445-51.
2. Mannucci PM, Tuddenham EGD. The hemophilias: from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
3. Kim HC, McMillan CW, White GC et al. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 1992; 79: 568-75.
4. Roth DA, Kessler CM, Pasi KJ et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600-6.
5. Saenko EL, Ananyeva NM, Shima M, Hauser CA, Pipe SW. The future of recombinant coagulation factors. J Thromb Haemost 2003; 1: 922-30.
6. Dinowitz M, Lie YS, Low MA et al. Recent studies on retrovirus-like particles in Chinese hamster ovary cells. Dev Biol Stand 1992; 76: 201-7.
7. Berting A, Farcet MR, Kreil TR. Virus susceptibility of Chinese hamster ovary (CHO) cells and detection of viral contaminations by adventitious agent testing. Biotechnol Bioeng 2010; 106: 598-607.
8. Kreil TR, Wieser A, Berting A et al. Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives. Transfusion 2006; 46: 1143-51.
9. Yunoki M, Tanaka H, Urayama T et al. Prion removal by nanofiltration under different experimental conditions. Biologicals 2008; 36: 27-36.
10. Silveira JR, Raymond GJ, Hughson AG et al. The most infectious prion protein particles. Nature 2005; 437: 257-61.
11. Burnouf T, Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 2003; 9: 24-37.
12. Morfini M, Mannucci PM, Mariani G et al. Evaluation of prophylactic replacement therapy in haemophilia B. Scand J Haematol 1976; 16: 41-7.
13. Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003; 9: 272-8.
14. Shapiro AD, Di PJ, Cohen A et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood 2005; 105: 518-25.
15. Klukowska A, Laguna P, Svirin P, Shiller E, Vdovin V. Efficacy and safety of OCTANINE F in children with haemophilia B. Haemophilia 2008; 14: 531-8.
16. ®, a high-purity factor IX concentrate, in patients with severe haemophilia B. Haemophilia 2011; 17: 590-6.
17. ®prophylaxis in children less than 6 years of age with severe hemophilia B. Haemophilia 2010; 16: 460-8.
18. Siegmund B, Richter H, Pollmann H. Prophylaxis in haemophilia B. Prevention of bleeds and FIX consumption. Hamostaseologie 2010; 30: 35-8.
19. Chambost H, Goudemand J, Briquel ME et al. Five-year post-marketing surveillance of haemophilia B patient receiving a factor IX concentrate: final results [abstract]. J Thromb Haemost 2011; 9(Suppl. 2): 371.
20. ®a high-purity Factor IX concentrate, in patients with severe haemophilia B. Haemophilia 2010; 16: 240-6.
21. ®), results of phase III and IV clinical studies. Haemophilia 2011; 17: 439-45.
22. Valentino LA, Plushch O, Rusen L et al. A multicenter, open-label study to compare on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in subjects with hemophilia B. J Thromb Haemost 2011; 9(Suppl. 2): 357.
23. Verbruggen B, Novakova I, Wessels H et al. The Nijmegen modification of the Bethesda Assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
24. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591-605.
25. Ewing NP, Kasper CK. In vitro detection of mild inhibitors to factor VIII in hemophilia. Am J Clin Pathol 1982; 77: 749-52.
26. Whelan SF, Hofbauer CJ, Horling FM et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 2013; 121: 1039-48.
27. Maruish ME (Ed.). User's Manual for the SF-36v2 Health Survey, 3rd edn. Lincoln, RI: Quality Metric Incorporated, 2011.
28. ©: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia 2007; 13: 233-43.
29. White G, Shapiro A, Ragni M et al. Clinical evaluation of recombinant factor IX. Semin Hematol 1998; 35: 33-8.
30. Kisker CT, Eisberg A, Schwartz B; Mononine Study Group. Prophylaxis in factor IX deficiency product and patient variation. Haemophilia 2003; 9: 279-84.
31. Björkman S. A commentary on the differences in pharmacokinetics between recombinant and plasma- erived factor IX and their implications for dosing. Haemophilia 2011; 17: 179-84.
32. Ewenstein BM, Joist JH, Shapiro AD et al. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002; 42: 190-7.
33. Bond M, Jankowski M, Patel H et al. Biochemical characterization of recombinant factor IX. Semin Hematol 1998; 35(Suppl. 2): 11-7.
34. White GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997; 78: 261-5.
35. Berntorp E, Fischer K, Miners A. Models of prophylaxis. Haemophilia 2012; 18(Suppl. 4): 136-40.
36. Tagliaferri A, Franchini M, Coppola A et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008; 14: 945-51.
37. Valluri S, Flood E, Pocoski J et al. What is it like to have a joint bleed? The perspective of adults and adolscents with hemophilia A [abstract]. Haemophilia 2012; 18(Suppl. 1): 38.
38. Valentino LA, Walsh CE, Reding MT, Young GA, Levendoglu-Tugal O, Cooper DL. Patient- and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE). Haemophilia 2012; 18: 554-60.
39. Horling FM, Whelan SF, Hofbauer CJ, Allacher P, Scheiflinger F, Reipert BM. Prevalence of self-reactive antibodies against coagulation factors found in healthy individuals. Proceedings of the 57th Annual Meeting of Thrombosis and Haemostasis Research, 20-23 February, 2013. Munich, Germany.
40. Fukui H, Yoshioka A, Shima M et al. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A. Int J Hematol 1991; 54: 419-27.